Brokerages Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $98.11

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned a consensus rating of “Moderate Buy” from the twenty ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $98.11.

DXCM has been the subject of a number of research analyst reports. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler decreased their price target on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Mizuho started coverage on DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price objective on the stock. Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd.

DexCom Trading Down 0.2%

Shares of NASDAQ DXCM opened at $85.48 on Tuesday. DexCom has a fifty-two week low of $57.52 and a fifty-two week high of $132.09. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market cap of $33.52 billion, a price-to-earnings ratio of 59.78, a PEG ratio of 2.30 and a beta of 1.43. The business’s 50 day moving average price is $72.01 and its 200-day moving average price is $77.64.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 earnings per share. On average, sell-side analysts expect that DexCom will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Institutional investors have recently made changes to their positions in the business. Private Trust Co. NA raised its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after acquiring an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of DexCom during the first quarter valued at about $27,000. Optiver Holding B.V. purchased a new position in shares of DexCom in the 4th quarter valued at approximately $33,000. Finally, TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.